Evolving Concepts and Their Application to Cancer Immunotherapy in 2017 - prIME Oncology
Expert Perspectives
Expert Perspectives

Evolving Concepts and Their Application to Cancer Immunotherapy in 2017

Not a member of My prIME? Join now for instant access.

These concise videos and downloadable slides provide insight on the rationale for immunotherapy and summarize the clinical trial data supporting the current or potential future inclusion of a checkpoint inhibitor in the treatment pathway of bladder, breast, lung, and renal cancers. Key differences between the available and emerging agents are highlighted and the challenges of patient selection addressed.

To access the downloadable slides from our symposium Evolving Concepts and Their Application to Cancer Immunotherapy in 2017, please click here.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit

Release Date

Release Date

May 5, 2017

Expiration Date

May 5, 2018

  • Christian U. Blank, MD, PhDNetherlands Cancer Institute
    Amsterdam, the Netherlands
  • Solange Peters, MD, PhDUniversity of Lausanne
    Lausanne, Switzerland
  • Thomas Powles, MBBS, MRCP, MDBarts Cancer Institute
    Queen Mary University of London
    London, United Kingdom
  • Peter Schmid, MD, PhD, FRCPQueen Mary University of London
    Barts Hospital
    London, United Kingdom
  • Immunotherapy in:
    • Bladder cancer
    • Breast cancer
    • Lung cancer
    • Renal cancer
  • prIME Points™

This educational activity is specifically designed to meet the needs of medical oncologists, translational scientists, and other healthcare professionals interested in cancer immunotherapy.

After successful completion of this educational activity, participants should be able to:

  • Describe the role of checkpoint inhibitors in the treatment pathways for bladder, breast, lung, and renal cancers
  • Evaluate the use of biomarkers in treatment selection for patients with these diseases

This activity has been funded by Roche Products Limited/Hoffman la Roche.
Roche Products Limited/Hoffman la Roche has had no control over the educational content of this activity.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Blank has disclosed that he received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. He also performed contracted research for Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Peters has nothing to disclose in relation to this activity. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Powles has disclosed that he has received consulting fees and participated in trials for AstraZeneca, Merck, Novartis, Pfizer, and Roche. He has performed contracted research for AstraZeneca, Merck, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schmid has disclosed that he has received grants/research support (with funds going to his institution) from Astellas, AstraZeneca, Medivation, Novartis, Oncogenex, and Roche/Genentech. He has also received consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, and Puma. His spouse has received other fees from Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – performed contracted research for or received research support from Amgen and Bayer
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

 

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.